David W. Taylor
Affiliations: | 2016- | Molecular Biosciences | University of Texas at Austin, Austin, Texas, U.S.A. |
Website:
http://cryoem.cns.utexas.edu/about.htmlGoogle:
"David Taylor"Mean distance: (not calculated yet)
Parents
Sign in to add mentor| Hong-Wei Wang | grad student | 2013 | Yale (Physics Tree) | |
| (Structural Basis for RNA Processing by Human Dicer.) | ||||
| Jennifer A. Doudna | post-doc | 2014-2016 | UC Berkeley | |
| Eva Nogales | post-doc | 2014-2016 | UC Berkeley | |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Taylor D, Schwartz E, Bravo J, et al. (2023) Type III CRISPR-Cas effectors act as protein-assisted ribozymes during RNA cleavage. Research Square |
| O'Brien RE, Bravo JPK, Ramos D, et al. (2023) Structural snapshots of R-loop formation by a type I-C CRISPR Cascade. Molecular Cell |
| Bravo JPK, Hallmark T, Naegle B, et al. (2023) RNA targeting unleashes indiscriminate nuclease activity of CRISPR-Cas12a2. Nature. 613: 582-587 |
| Yelland JN, Bravo JPK, Black JJ, et al. (2022) A single 2'-O-methylation of ribosomal RNA gates assembly of a functional ribosome. Nature Structural & Molecular Biology |
| Bravo JPK, Aparicio-Maldonado C, Nobrega FL, et al. (2022) Structural basis for broad anti-phage immunity by DISARM. Nature Communications. 13: 2987 |
| Schwartz EA, McBride TM, Bravo JPK, et al. (2022) Structural rearrangements allow nucleic acid discrimination by type I-D Cascade. Nature Communications. 13: 2829 |
| Bravo JPK, Liu MS, Hibshman GN, et al. (2022) Structural basis for mismatch surveillance by CRISPR-Cas9. Nature |
| Steens JA, Zhu Y, Taylor DW, et al. (2021) SCOPE enables type III CRISPR-Cas diagnostics using flexible targeting and stringent CARF ribonuclease activation. Nature Communications. 12: 5033 |
| Zhou Y, Bravo JPK, Taylor HN, et al. (2021) Structure of a type IV CRISPR-Cas ribonucleoprotein complex. Iscience. 24: 102201 |
| Bravo JPK, Dangerfield TL, Taylor DW, et al. (2021) Remdesivir is a delayed translocation inhibitor of SARS-CoV-2 replication. Molecular Cell |